Casamba merges with HealthWyse, TherapySource

Casamba announced the company has merged with HealthWyse of Boston and TherapySource of Birmingham, Alabama.

HealthWyse and TherapySource will help in fulfilling Casamba’s mission to develop a comprehensive solution to use across post-acute care networks. By being able to deliver information across many platforms, the newly formed company hopes to lower costs, increase value and optimize patient care.

“Our healthcare clients need better systems and more integration,” said David McMullen, Chief Therapy Officer for TherapySource. “The combination of these three market leaders, working together, empowers us to drive revolutionary workflow innovation through a single platform.”

“We are pleased to join forces with HealthWyse and TherapySource to enhance our offering, and support current and future clients of all three organizations with superior software and services,” said Ronnie Amrany, President and CEO of Casamba. “In this era of bundled payments, we will enable providers to optimize their delivery of care across the continuum, while tightening their revenue cycle.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.